| Size | Price | Stock | Qty |
|---|---|---|---|
| 1g |
|
||
| 5g |
|
||
| Other Sizes |
| Targets |
Its primary application is as a catalyst in organic synthesis, with a specific focus on promoting carbon-carbon bond formation. The palladium center facilitates oxidative addition and transmetalation steps crucial for cross-coupling reactions.
|
|---|---|
| ln Vitro |
PdCl2(Amphos)2 exhibits high catalytic activity in Suzuki-Miyaura cross-coupling reactions. It is effective with aryl halides, including challenging 5- and 6-membered heteroaryl chlorides. Its air-stable nature makes it more convenient to handle compared to many other palladium catalysts that require inert atmosphere conditions.
|
| ln Vivo |
Specific in vivo activity is not applicable as this compound is a chemical reagent used for synthesis, not a drug. Its utility is in the preparation of pharmaceutical intermediates and other organic compounds in a laboratory setting. The catalyst itself is not administered to living organisms for therapeutic effect.
|
| Enzyme Assay |
In a typical procedure, a reaction vessel is charged with the aryl halide, boronic acid or ester, base, and solvent. The PdCl2(Amphos)2 catalyst (e.g., ca. 0.060 mmol) is then added. The mixture is stirred under specified conditions (e.g., temperature, time). The reaction progress is monitored by techniques like TLC or HPLC, and the product is isolated by standard workup and purification.
|
| Cell Assay |
Cell-based assays are not applicable as PdCl2(Amphos)2 is a synthetic catalyst. Its activity is evaluated in chemical reactions rather than biological systems. The focus is on its ability to facilitate chemical transformations, which is assessed by product yield, purity, and reaction rate.
|
| Animal Protocol |
Animal studies are not conducted with PdCl2(Amphos)2 as it is not a therapeutic agent. Its use is confined to the laboratory for chemical synthesis. The "in vivo" context for this compound would refer to its performance in a chemical reaction mixture, not within a living organism.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties are not relevant as PdCl2(Amphos)2 is a research reagent and not a drug. Its chemical properties are characterized, including molecular weight (708.07 g/mol) and formula (C32H56Cl2N2P2Pd). It is used in organic solvents and its stability in air is a key practical feature.
|
| Toxicity/Toxicokinetics |
Toxicological data are not typically provided for this catalyst as it is a chemical reagent for research use only. However, as it is a palladium-containing compound, it is generally considered hazardous. Standard safety precautions for handling heavy metals and organometallic compounds should be followed. A Safety Data Sheet (SDS) should be consulted.
|
| Additional Infomation |
PdCl2(Amphos)2 is a commercially available catalyst used in academic and industrial research for the synthesis of complex organic molecules, including pharmaceuticals and agrochemicals. Its air stability and high activity make it a preferred choice for Suzuki-Miyaura cross-coupling reactions, particularly in medicinal chemistry for constructing biaryl motifs found in many drug candidates.
|
| Molecular Formula |
C32H56CL2N2P2PD
|
|---|---|
| Molecular Weight |
708.07
|
| Exact Mass |
706.233
|
| CAS # |
887919-35-9
|
| PubChem CID |
11714597
|
| Appearance |
Light yellow to yellow solid powder
|
| Boiling Point |
349.1ºC at 760 mmHg
|
| Flash Point |
164.9ºC
|
| LogP |
10.292
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
39
|
| Complexity |
240
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC(C)(C)P(C1=CC=C(C=C1)N(C)C)C(C)(C)C.CC(C)(C)P(C2=CC=C(N(C)C)C=C2)C(C)(C)C.Cl[Pd]Cl
|
| InChi Key |
DWOZNANUEDYIOF-UHFFFAOYSA-L
|
| InChi Code |
InChI=1S/2C16H28NP.2ClH.Pd/c2*1-15(2,3)18(16(4,5)6)14-11-9-13(10-12-14)17(7)8;;;/h2*9-12H,1-8H3;2*1H;/q;;;;+2/p-2
|
| Chemical Name |
4-ditert-butylphosphanyl-N,N-dimethylaniline;dichloropalladium
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: (1). This product requires protection from light (avoid light exposure) during transportation and storage. (2). Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 2 mg/mL (2.82 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.4123 mL | 7.0614 mL | 14.1229 mL | |
| 5 mM | 0.2825 mL | 1.4123 mL | 2.8246 mL | |
| 10 mM | 0.1412 mL | 0.7061 mL | 1.4123 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
